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AbstrACt
background Randomised controlled trials can provide 
evidence relevant to assessing the equity impact of 
an intervention, but such information is often poorly 
reported. We describe a conceptual framework to identify 
health equity-relevant randomised trials with the aim of 
improving the design and reporting of such trials.
Methods An interdisciplinary and international research 
team engaged in an iterative consensus building process 
to develop and refine the conceptual framework via 
face-to-face meetings, teleconferences and email 
correspondence, including findings from a validation 
exercise whereby two independent reviewers used the 
emerging framework to classify a sample of randomised 
trials.
results A randomised trial can usefully be classified 
as ‘health equity relevant’ if it assesses the effects of 
an intervention on the health or its determinants of 
either individuals or a population who experience ill 
health due to disadvantage defined across one or more 
social determinants of health. Health equity-relevant 
randomised trials can either exclusively focus on a single 
population or collect data potentially useful for assessing 
differential effects of the intervention across multiple 
populations experiencing different levels or types of social 
disadvantage. Trials that are not classified as ‘health equity 
relevant’ may nevertheless provide information that is 
indirectly relevant to assessing equity impact, including 
information about individual level variation unrelated to 
social disadvantage and potentially useful in secondary 
modelling studies.
Conclusion The conceptual framework may be used to 
design and report randomised trials. The framework could 
also be used for other study designs to contribute to the 
evidence base for improved health equity.
IntroduCtIon
Many countries have policy documents that 
reflect concern for social justice, with a goal 
to redressing disparities in health both within 
and between countries.1 For example, within 
Canada, the difference in life expectancy 
between Indigenous and general populations 
is on average 10 years.2 Differences in health 
between individuals or population groups 
within society, or health inequalities, are 
labelled ‘inequities’ when considered unfair.3 
There are differing views on what counts as 
unfair and moral judgements about fairness 
may vary over time and between cultures.4 
For example, men have a shorter life expec-
tancy (with less disability) than women, and 
there is controversy about whether this is 
inequitable.5 Two common guiding princi-
ples, frequently advocated in public health 
strengths and limitations of this study
 ► Randomised controlled trials ('randomised trials') 
can provide evidence on both the impact of 
interventions in general and differential impacts in 
different populations. This is critical for decision-
making to address inequity.
 ► A consensus building process was used to develop 
and validate a conceptual framework to identify and 
classify health equity-relevant randomised trials.
 ► The proposed conceptual framework engages users 
in a deliberative process to design and report studies 
to provide evidence that is useful to understand 
the distribution of effects rather than only average 
effects.
 ► A limitation is that the analysis and publishing of 
disaggregated data can be expensive and may not 
be desirable for all randomised trials.
 ► The conceptual framework may be used to design 
health equity-relevant randomised trials (as well 
as other study types) and to identify health equity-
relevant studies that contribute to an evidence base 
that improves overall health and health equity.
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policy documents, are that health inequalities can be 
considered unfair when they are potentially avoidable by 
organised social action and when the situation that causes 
poor health is out of the control of those affected.6 This 
includes situations where choices are severely restricted 
by social, historical, economical or built environments. 
The causes of health inequity are multidimensional and 
include factors described as social determinants of health 
and health sector factors. For the purposes of this paper, 
we choose to define health equity in this way to reflect 
our collective interests in social justice and the removal of 
social barriers posed by discrimination and stigmatisation 
which affect participation by individuals or populations in 
opportunities for better health.
Healthcare decisions in most countries are commonly 
guided by different types of evidence, among which 
clinical evidence based on randomised controlled trials 
(‘randomised trials’) usually holds particular prom-
inence. To be useful for health equity policy, consider-
ations for differences within and between groups and 
gradients of effects across socially stratifying factors are 
critical. Considering health equity is important to direct 
approaches that are either universal and intended to 
address health inequity for a whole population or that 
are focused and directed at a specific subgroup that expe-
riences health inequity. Improved reporting of health 
equity in randomised trials is important as some inter-
ventions can aggravate rather than reduce inequities 
(‘intervention-generated inequities’).7 A review of public 
health media campaigns for health behaviour revealed 
that health information provision was more effective in 
motivating behaviour change among socioeconomically 
advantaged groups and widened the observed gap in 
health behaviour between socioeconomically disadvan-
taged groups.7 Although improving average health is an 
important social goal, increased inequity is an undesir-
able side effect. The improved reporting of health equity 
implications of interventions is critical, and the increased 
use of randomised trial designs are promoted in the areas 
of public health8 and international development9 to build 
evidence that informs equity-oriented decisions.
Randomised trials provide evidence on the impact of 
an intervention and, in principle, can also assess their 
impact on health equity; however, randomised trials 
often fail to report relevant sociodemographic factors.10 
In addition, subgroup analyses, even when appropri-
ately powered are rarely conducted to assess whether the 
impact of the intervention differs across subgroups in 
society (eg, differential impact by socioeconomic status, 
place of residence).11 To address the poor reporting 
and analysis of equity impacts in randomised trials, we 
are assessing the need for additional reporting guide-
lines for randomised trials that provide evidence about 
potential impact on health equity.12 An extension of the 
internationally recognised Consolidated Standards for 
Reporting Trials (CONSORT) statement, an evidence-
based guideline to encourage completeness and transpar-
ency of reporting in randomised trials13 is under way. The 
purpose of this paper is to describe the development and 
validation of a conceptual framework to identify when a 
randomised trial provides evidence about health equity. 
The conceptual framework may be helpful for the design 
and reporting of randomised trials by trialists, funders, 
journal editors and other knowledge user groups.
Methods
We convened a collaborative research team and advi-
sory board including interdisciplinary and international 
knowledge users in a deliberative, consensus building 
process as part of a larger study described elsewhere.12 We 
searched for and did not find any frameworks to define an 
equity-relevant randomised trial.12 We then conducted a 
series of meetings that included representatives of poten-
tial knowledge user groups, including: bioethicists, clini-
cians, funders, journal editors, patient representatives, 
members of the public, policymakers, systematic review 
authors and trialists. We engaged in a process to define 
features of randomised trials that provide evidence about 
health equity, which we define as ‘health equity-relevant’ 
randomised trials.
As a first step, we agreed on an operational defini-
tion of health equity for our work on health equity in 
randomised trials, drawing on social determinants of 
health theory that describes how socially structured 
health disadvantage is experienced and perpetuated.14 
We agreed, for this context, that the term ‘health equity’ 
implies that ideally everyone can attain their full health 
potential and that no one should be disadvantaged from 
doing so because of their social position or other socially 
determined circumstance.15 Health equity addresses both 
access to healthcare and the broader concept of oppor-
tunities to achieve good health.6 Moreover, we recognise 
that there are a range of characteristics of individuals or 
populations across which health inequities may exist and 
that reasonable people hold different views about what 
counts as unfair.16
Evidence shows that across the social determinants of 
health for individuals and population groups, people may 
experience disparities in health status, access to services 
and the quality of care received.14 Social determinants 
may be multifactorial and interact with one another. 
They can also be dependent on the context and setting, 
such as the local political or social climate and the form 
of health systems in which individuals and populations 
are situated.17 One organising framework is ‘PROG-
RESS-Plus’ that depicts social determinants of health 
and enables the examination of the relationships within 
and between the multiple, interacting and socially struc-
tured characteristics that may influence the opportunities 
for health of individuals and populations: Place of resi-
dence, Racei/ethnicity/culture/language, Occupation, 
i  We adopt the American Anthropological Society (1998) statement 
on race: ‘Present-day inequalities between so-called ‘racial’ groups 
are not consequences of their biological inheritance but products of 
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Gender/Sex, Religion, Education, Socioeconomic status, 
and Social capital.18–20 Due to advances in thinking about 
causal associations/linkages between degree of control 
in the living environment and socioeconomic inequities 
in health-related outcomes, ‘Control’ was included with 
‘Social Capital’.21 PROGRESS-‘Plus’ represents addi-
tional context-specific personal or setting characteristics 
that may be associated with health inequities and that are 
relevant to our study: (1) individual characteristics, for 
example, disability, age, sexual orientation; (2) features 
of relationships with effects on power differentials that 
impact personal autonomy, for example, children who 
suffer passive smoking because their parents smoke in the 
home and (3) time-dependent transitions, for example, 
migration and/or refugee status.22 23 The degree to which 
PROGRESS-Plus characteristics are associated with health 
inequity depends on time, place and interaction between 
the different dimensions.
A conceptual framework was developed and feedback 
on the concepts and format of the conceptual framework 
was invited from over 40 clinicians and methodologists 
in face-to-face meetings, teleconferences and email. 
These communications used randomised trial examples 
to structure conversation and debate about the meaning 
of ‘health equity relevant’. Furthermore, we gathered 
opinions from many others in local seminars and at 
international conferences. This feedback was incorpo-
rated through iterative adjustments to the conceptual 
framework.
The conceptual framework was tested with the research 
team and advisory board.12 A search for randomised trials 
was designed with a librarian scientist (JM) in MEDLINE, 
using text words and subject headings for the concepts 
of PROGRESS-Plus and a validated filter for randomised 
trials24 (see online supplementary appendix A). We devel-
oped this search by testing whether it identified a refer-
ence set of 10 articles classified as health equity relevant 
according to our framework.12 The search was run from 
2013 to 2015 and generated 4316 hits. Of these, 1025 were 
judged to be equity relevant based on title and abstract 
historical and contemporary social, economic, educational, and polit-
ical circumstances’.
screening. These 1025 articles were arranged in random 
order, then screened in full text by two independent 
reviewers for eligibility using the criteria developed to 
define a health equity-relevant trial. We screened for eligi-
bility until we identified 200 health equity-relevant trials, 
selected as the sample size for a concurrent methods 
study (in progress). The sample of trials was tested with 
the conceptual framework for consistency of concepts. 
Conversation and debate about concepts occurred and 
led to consensus around five aspects of randomised trials, 
and the definition was revised to reflect the consensus 
reached in these discussions. The research team and 
advisory board confirmed the final adjustments to the 
conceptual framework (figure 1).
results
A randomised trial is considered to provide health equi-
ty-relevant evidence if it actually or potentially assesses 
the effects of an intervention on the health or its deter-
minants of either individuals or a population who expe-
rience ill health due to social disadvantage (figure 2). 
These randomised trials can either exclusively focus on 
individuals or populations experiencing socially struc-
tured disadvantage or consist of a mixed group and collect 
data potentially useful for assessing differential effects of 
the intervention across PROGRESS-Plus characteristics 
(table 1). The evidence from these randomised trials may 
be used to mitigate socially structured health disadvan-
tage, that is, contribute to understanding of the extent to 
which the intervention in question is effective in popu-
lation groups who experience disadvantage. To identify 
200 health equity-relevant randomised trials, 643 articles 
were screened. Screening confirmed that the criteria for 
health equity relevance could be applied to randomised 
trials consistently.
Five aspects of randomised trials are reported as find-
ings and reflect the debated points during the validation 
of the conceptual framework concepts. We considered 
five aspects of randomised trials and their relevance to 
define a randomised trial as health equity relevant: (1) 
type of interventions, (2) stated objective about equity, 
(3) estimation of differential impacts, (4) levels of health 
equity-relevant data and (5) setting and context.
type of intervention
We agreed that the type of intervention (eg, pharma-
cological, non-pharmacological, health systems) was 
not relevant to identifying a randomised trial as health 
equity relevant. Although health equity is sometimes 
considered relevant only to public health or upstream 
interventions, we found many examples of clinical or 
pharmacological interventions that met our health equi-
ty-relevant definition. For example, we considered a 
randomised trial that evaluated a clinical intervention to 
promote asthma education for individual inner-city child 
patients with asthma that improved health outcomes25 to 
be health equity relevant.
Figure 1 Description of the conceptual framework 
development process.
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Figure 2 The conceptual framework.
Table 1 Examples of health equity-relevant studies
Includes individuals or a population that experiences ill health due to social disadvantage (defined across PROGRESS-Plus).
Assesses the effects of the intervention on the health or its determinants of either individuals or a population who experience 
ill health due to disadvantage defined across one or more social determinants of health.
Either exclusively focus on individuals or a population or includes a mixed group
‘PROGRESS’ criteria examples ‘Plus’ criteria examples
Assesses effectiveness of the 
intervention solely for groups 
who are considered to be at a 
social disadvantage
Assesses effectiveness of 
the intervention for groups 
considered to be at a social 
disadvantage compared with 
other groups considered to be at 
less of a disadvantage
Assesses effectiveness 
of the intervention solely 
for groups who are 
considered to be at a social 
disadvantage
Assesses effectiveness of 
the intervention for groups 
considered to be at a social 
disadvantage compared with 
other groups considered to be 
at less of a disadvantage
A trial of an intervention to 
prevent domestic violence in 
Indigenous communities.39
A trial of an informed choice 
invitation on uptake of screening 
for diabetes in primary care 
assessed differences in 
effectiveness by socioeconomic 
status.40
A trial that tests a vocational 
intervention aimed at 
improving employment 
for people diagnosed with 
severe mental illness.41
A trial of a schooling 
conditional cash transfer 
programme on the behaviour 
of young women assessed 
effectiveness separately 
based on enrolment status at 
the start of the study: those 
who have dropped out versus 
stayed in school.42
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stated objective about equity
We found that a randomised trial did not need to have 
an explicit objective about improving health equity to be 
classified as health equity relevant. For example, a study 
that implemented a weight loss intervention for native 
Hawaiians and other Pacific Islanders did a secondary 
analysis of sociodemographic variables26 but did not iden-
tify health equity, inequalities or disparities as part of its 
objectives. However, the analysis of effects across income 
groups provides evidence about effectiveness of treat-
ment for a population that is potentially disadvantaged in 
relation to opportunities for health.
estimate of differential impacts
For the sake of transparency and to assess whether 
observed interactions are likely to result from multiple 
comparisons, it is critically important that an a priori 
plan of analysis is described that all examined interac-
tions are reported on. Any post hoc subgroup analyses 
of randomised trial data (eg, across equity characteris-
tics) are at risk of identifying spurious interactions and 
need to be interpreted with caution. There is, however, 
increasing recognition that data disaggregation is partic-
ularly important, such as analyses across sex/gender.27 
The exploration of interactions should be situated within 
a theoretical perspective28 and/or empirical evidence as 
a base from which effect measure interactions may be 
assessed. For health equity, it is important to also consider 
gradients of effect across social stratifying factors such as 
income quintiles or with indices that reflect distribution 
such as the concentration index.29
Many randomised trials include a broad range of 
population groups, with limited details on sociodemo-
graphic characteristics and do not provide disaggre-
gated data that could be used to assess whether effects 
of interventions differ between groups within the popu-
lation. Furthermore, some randomised trials use detailed 
sociodemographic data to adjust analyses for baseline 
imbalances rather than deliberately exploring whether 
sociodemographic characteristics modify the effect of 
the interventions under study, thus losing the ability to 
assess similarities or differences in effects across these 
characteristics.30 This represents a missed opportunity for 
providing evidence about equity.
When trialists do not have a prespecified primary 
research objective of estimating differential impacts 
but nevertheless collect data on social determinants of 
health characteristics, then an opportunity exists to assess 
subgroup effects. The scope for a randomised trial to 
contribute health equity data may not be immediately 
apparent to the randomised trial designer. For example, 
even if each trial’s statistical power to identify differen-
tial effects may be low, combining data from several trials 
(eg, in meta-analyses) may substantially enhance statis-
tical precision to identify and estimate the strength of 
such interactions. Data from randomised trials can also 
be combined with data from observational studies or 
analysed with methods that incorporate explicit Bayesian 
priors and/or theories about differential impacts based 
on well-established bodies of evidence and theory. The 
problem of multiple tests and the effects on power can 
be addressed if all analyses of interaction are shown, as 
well as whether the interaction is defined as departure 
from ‘multiplicativity’ or ‘additivity’ or both. These inter-
action analyses should be described31 in the randomised 
trial registration and in the protocol paper. It is our 
view that opportunities to provide health equity-relevant 
evidence should be considered up front in randomised 
trial conception and design and reported transparently. 
Thus, collecting data about outcomes across social deter-
minants of health may provide useful information for 
future and additional analyses, now greatly facilitated by 
global initiatives to allow data sharing.32
It is equally important to report analyses where no 
differences in effects are found since these may identify 
hypotheses for testing in future studies and any failure 
to identify effects due to low statistical power. If a health 
programme is equally effective in relative terms, if disad-
vantaged populations have a higher baseline risk, there 
will be a greater reduction in absolute events for disad-
vantaged populations.33 Such information is valuable for 
understanding the impact and potential for interventions 
to improve or exacerbate health inequities.
levels of health equity-relevant data
According to our conceptual framework, an equity-rel-
evant randomised trial may both focus on individuals 
and population experiencing socially structured disadvan-
tage and collect data on differential impacts of the inter-
vention in the form of subgroup effects, thus providing 
more than one level of health equity-relevant data. For 
example, a randomised trial of a video module that 
aimed to increase the use of a US poison centre by low-in-
come parents is focused on a population experiencing 
social disadvantage, but it also provides evidence across 
language proficiency strata by conducting a subgroup 
analysis.34 The use of different intervention approaches 
is complementary and aims to address the multifactorial 
and intersecting characteristics of populations and indi-
viduals that affect health outcomes.
setting and context
The population characteristics that influence socially 
structured disadvantage depend on the broader features 
of setting and context such as social, historical and political 
systems and require careful consideration. For example, 
a study with Japanese citizens conducted in Japan would 
not be classified as an equity-relevant randomised trial 
unless the participants were also considered to be disad-
vantaged across another dimension such as sex/gender 
or income.
We recognise that health equity concerns arise from an 
array of characteristics; judgments about particular indi-
vidual or population health determinants are concerns 
for inequity and may be more difficult because of the need 
to carefully consider the context of the randomised trial 
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and characteristics, such as age or disability. Studies that 
report interventions related to overcoming health disad-
vantage need to consider the relationship between the 
intervention and how it might relate to equity/inequity, 
such as an intervention to promote school enrolment and 
health outcomes between participants who have dropped 
out versus stayed in school.35
dIsCussIon
Operationalising a definition of a health equity-relevant 
randomised trial required consideration of broader 
issues and meanings of social justice informed by values, 
context and the impact of different social arrange-
ments. Our conceptual framework engages users to 
consider and identify the many instances of health 
equity-relevant evidence and the potential contribu-
tions to broader societal dialogues. The evidence from 
these randomised trials may be used to mitigate socially 
structured health disadvantage, that is, contribute to 
understanding of the extent to which the intervention 
in question is effective in population groups who expe-
rience disadvantage.
The conceptual framework is proposed as a way to 
identify and operationalise understandings about how 
randomised trials can provide evidence about health 
equity and in particular complements two previous 
intervention frameworks related to improving health 
equity. Margaret Whitehead’s typology is based on the 
underlying theory of change and guides consideration 
of appropriate application of interventions to address 
health inequity; interventions fall into one of four main 
categories: strengthening individuals, strengthening 
communities, improving living and working conditions 
and promoting healthy macropolicies.15 Hilary Graham’s 
typology identifies three main approaches: addressing 
health inequity gaps, gradients or targeted approaches.36 
Our conceptual framework builds on these classification 
systems and suggests ways randomised trials can provide 
health equity-relevant evidence for an intervention, even 
when providing evidence about equity is not the central 
aim. Our conceptual framework has potential applica-
tions to inform other study designs and is not limited to 
that of randomised trials.
It is our view that opportunities to provide health equi-
ty-relevant evidence should be considered up front in 
randomised trial conception and design and reported 
transparently. While different users will hold different 
definitions and priorities in regard to disadvantage and 
opportunities for health, we argue that consideration 
of individual or population characteristics and societal 
context is of paramount importance. Moreover, consid-
eration of equity aligns with and supports an approach 
to decision-making that enables consideration of distri-
butional goals and outcomes aimed at addressing health 
inequity.36 Knowledge about differential effects (or lack 
thereof) using social determinants of health theory, oper-
ationalised across PROGRESS-Plus characteristics can 
contribute to build knowledge aimed at improved appli-
cation of effective interventions.
The approach to health equity supported by the concep-
tual framework promotes thinking about randomised 
trials as more than just a means of developing evidence 
about average efficacy or effectiveness. It highlights 
opportunities for all randomised trials to contribute to a 
broader social agenda about reducing health inequity. In 
doing so, it upholds international policy on ‘research for 
health’ that advocates for the development of research 
methods to promote better knowledge and standardisa-
tion of reporting mechanisms.37 38
limitations and strengths
A limitation of this approach is that analysing and 
publishing disaggregated data can be expensive, and it 
is not desirable for all randomised trials to do subgroup 
analyses by PROGRESS-Plus characteristics. We propose 
that, when possible, data on equity-relevant characteris-
tics be collected, even when the study may not have suffi-
cient power to perform subgroup analyses. In this way, 
data about characteristics linked to health equity may 
be made available for other researchers to use in pooled 
analyses, modelling or systematic reviews. Additionally, 
other knowledge sources/systems are essential to under-
stand health inequities and not all social determinants of 
health are a source of ‘disadvantage’. As well, relation-
ships within and between social determinants of health 
mean that there may be a need to explicitly identify the 
factors that are relevant and therefore have been focused 
on, as not every facet of inequity is relevant to every 
research question. The proposed conceptual framework, 
therefore, is designed to engage users in deliberation 
about designing and reporting studies that can provide 
evidence useful to understand distribution of effects, 
rather than only average effects. Strengths of the concep-
tual framework are the use of a collaborative approach to 
development and the iterative testing of the framework 
with examples of randomised trials.
ConClusIon
The conceptual framework defines features of health 
equity-relevant trials that can be used to design and 
report both randomised trials and other study designs to 
improve the evidence base about how to improve health 
equity. Opportunities to provide health equity-relevant 
evidence should be considered upfront in trial concept 
and design. The conceptual framework can provide a 
stimulus to build knowledge about effects of interven-
tions on health equity and is a first step to improve appli-
cation of effective interventions and to build evidence 
that is of greatest relevance and use to individuals and 
populations.
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